| Name | MT-DADMe-ImmA |
| Description | MT-DADMe-ImmA (MTDIA) is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP, Ki: 90 pM). |
| Cell Research | Cell viability is evaluated using the Alamar Blue assay. Cells are seeded onto 96-well plates at a density of 10^4 cells/well and incubated with increasing concentrations of MT-DADMe-ImmA (100 pM to 100 μM) for 4 days at fixed MTA concentrations (0, 5, 10, and 20 μM) [2]. |
| Animal Research | Tumors were established in mice for 5 days prior to oral or intraperitoneal treatments with MT-DADMe-ImmA. Mice are treated with an oral dose of 21 mg/kg or an intraperitoneal dose of 5 mg/kg/day MT-DADMe-ImmA [2]. |
| In vitro | Treatment of cultured cells with MTA and MT-DADMe-ImmA inhibit MTAP, increase cellular MTA concentrations, decrease polyamines, and induce apoptosis in FaDu and Cal27, two head and neck squamous cell carcinoma cell lines. MT-DADMe-ImmA alone does not induce apoptosis in any cell line [2]. |
| In vivo | MTAP activity slowly returns, giving a biological half-life for the action of oral MT-DADMe-ImmA of 6.3 days. The time-dependent growth of FaDu tumors in immunodeficient mice is suppressed by oral or intraperitoneal treatment with MT-DADMe-ImmA [2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.82 mM), Sonication is recommended.
DMSO : 50 mg/mL (170.42 mM), Sonication is recommended.
|
| Keywords | MT-DADMe-ImmA | MTDADMeImmA | MTAP | MT DADMe ImmA | Inhibitor | inhibit |
| Inhibitors Related | MAK-683 hydrochloride | SNDX-5613 | Tazemetostat | Piribedil | XY1 | UNC 0631 | （Iso）-Flavokawain A | EPZ015666 | iso-Azalansta | AMI-1 free acid | MS37452 | MRTX-1719 |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Bioactive Compounds Library Max |
United States
